143 related articles for article (PubMed ID: 21991862)
1. Meeting the challenges and burdens associated with hereditary angioedema.
Toscani M; Riedl M
Manag Care; 2011 Sep; 20(9):44-51. PubMed ID: 21991862
[TBL] [Abstract][Full Text] [Related]
2. Economic costs associated with acute attacks and long-term management of hereditary angioedema.
Wilson DA; Bork K; Shea EP; Rentz AM; Blaustein MB; Pullman WE
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):314-20. PubMed ID: 20408341
[TBL] [Abstract][Full Text] [Related]
3. Managed care implications of hereditary angioedema.
Cardarelli W
Am J Manag Care; 2013 Jun; 19(7 Suppl):s119-24. PubMed ID: 23844784
[TBL] [Abstract][Full Text] [Related]
4. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.
Lumry WR; Castaldo AJ; Vernon MK; Blaustein MB; Wilson DA; Horn PT
Allergy Asthma Proc; 2010; 31(5):407-14. PubMed ID: 20929608
[TBL] [Abstract][Full Text] [Related]
5. The burden of illness in patients with hereditary angioedema.
Banerji A
Ann Allergy Asthma Immunol; 2013 Nov; 111(5):329-36. PubMed ID: 24125136
[TBL] [Abstract][Full Text] [Related]
6. [Hereditary angioedema: new mechanisms and therapeutic options].
Reshef A; Leibovich I; Goren A; Kidon M
Harefuah; 2009 Aug; 148(8):529-34, 571. PubMed ID: 19899257
[TBL] [Abstract][Full Text] [Related]
7. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007.
Zilberberg MD; Jacobsen T; Tillotson G
Allergy Asthma Proc; 2010; 31(6):511-9. PubMed ID: 20964950
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in management and treatment of hereditary angioedema.
Sardana N; Craig TJ
Pediatrics; 2011 Dec; 128(6):1173-80. PubMed ID: 22065270
[TBL] [Abstract][Full Text] [Related]
9. Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial.
Javaud N; Fain O; Durand-Zaleski I; Launay D; Bouillet L; Gompel A; Sobel A; Woimant M; Rabetrano H; Petrovic T; Lapostolle F; Boccon-Gibod I; Reuter PG; Bertrand P; Coppere B; Floccard B; Kanny G; Martin L; Vicaut E; Adnet F
Trials; 2016 Apr; 17(1):225. PubMed ID: 27140403
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
11. Hereditary angioedema: current and emerging treatment options.
Levy JH; Freiberger DJ; Roback J
Anesth Analg; 2010 May; 110(5):1271-80. PubMed ID: 20418292
[TBL] [Abstract][Full Text] [Related]
12. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe.
Caballero T; Aygören-Pürsün E; Bygum A; Beusterien K; Hautamaki E; Sisic Z; Wait S; Boysen HB
Allergy Asthma Proc; 2014; 35(1):47-53. PubMed ID: 24268449
[TBL] [Abstract][Full Text] [Related]
13. HAE update: epidemiology and burden of disease.
Bernstein JA
Allergy Asthma Proc; 2013; 34(1):3-6. PubMed ID: 23406927
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of hereditary angioedema.
Johnston DT
J Am Osteopath Assoc; 2011 Jan; 111(1):28-36. PubMed ID: 21258014
[TBL] [Abstract][Full Text] [Related]
15. Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes.
Cardarelli WJ
Am J Manag Care; 2018 Aug; 24(14 Suppl):S308-S313. PubMed ID: 30132645
[TBL] [Abstract][Full Text] [Related]
16. Before and after, the impact of available on-demand treatment for HAE.
Christiansen SC; Bygum A; Banerji A; Busse P; Li H; Lumry W; Davis-Lorton M; Bernstein JA; Frank MM; Castaldo A; Long JF; Riedl M; Zuraw BL
Allergy Asthma Proc; 2015; 36(2):145-50. PubMed ID: 25715243
[TBL] [Abstract][Full Text] [Related]
17. The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology.
Bygum A; Aygören-Pürsün E; Caballero T; Beusterien K; Gholizadeh S; Musingarimi P; Wait S; Boysen H
BMC Dermatol; 2012 Apr; 12():4. PubMed ID: 22536794
[TBL] [Abstract][Full Text] [Related]
18. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
20. Challenges of C1-inhibitor concentrate self-administration.
Boysen HB; Bouillet L; Aygören-Pürsün E
Int Arch Allergy Immunol; 2013; 161 Suppl 1():21-5. PubMed ID: 23689241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
